For the quarter ending 2026-03-31, INBX has $183,967K in assets. $205,002K in debts. $161,657K in cash and cash equivalents.
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 161,657 | 124,220 | 153,088 | 186,567 |
| Accounts receivable-Related Party | - | 0 | 0 | 0 |
| Accounts receivable-Nonrelated Party | - | 0 | 110 | 237 |
| Other receivables | 186 | 177 | 727 | 730 |
| Prepaid expenses and other current assets | 9,498 | 8,435 | 7,498 | 6,430 |
| Total current assets | 171,341 | 132,832 | 161,423 | 193,964 |
| Property and equipment, net | 3,196 | 3,733 | 4,306 | 4,885 |
| Operating right-of-use asset | 5,052 | 5,535 | 6,004 | 6,460 |
| Other non-current assets | 4,378 | 4,378 | 5,738 | 6,809 |
| Total assets | 183,967 | 146,478 | 177,471 | 212,118 |
| Accounts payable | 8,762 | 5,944 | 6,773 | 8,292 |
| Accrued expenses | 15,342 | 25,529 | 26,963 | 28,478 |
| Current portion of operating lease liability | 2,408 | 2,326 | 2,247 | 2,169 |
| Total current liabilities | 26,512 | 33,799 | 35,983 | 38,939 |
| Long-term debt, net | 174,994 | 100,559 | 99,917 | 99,279 |
| Non-current portion of operating lease liability | 3,496 | 4,127 | 4,741 | 5,341 |
| Total liabilities | 205,002 | 138,485 | 140,641 | 143,559 |
| Common stock, 0.0001 par value 120,000,000 shares authorized as of march31, 2026 and december31, 2025 14,607,286 shares issued and outstanding as of march31, 2026 and 14,577,609 shares issued and outstanding as of december31, 2025 | 1 | 1 | 1 | 1 |
| Additional paid-in-capital | 258,592 | 254,179 | 250,182 | 246,655 |
| Accumulated deficit | -279,628 | -246,187 | -213,353 | -178,097 |
| Total stockholders equity (deficit) | -21,035 | 7,993 | 36,830 | 68,559 |
| Total liabilities and stockholders equity (deficit) | 183,967 | 146,478 | 177,471 | 212,118 |
Inhibrx Biosciences, Inc. (INBX)
Inhibrx Biosciences, Inc. (INBX)